>>Signaling Pathways>> Microbiology & Virology>> Parasite>>Nimorazole

Nimorazole (Synonyms: Acterol, Naxofem, Naxogin, Nitrimidazine, NSC 107524)

Catalog No.GC11113

2-니트로이미다졸인 니모라졸(K-1900)은 저산소 세포 방사선 증감제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Nimorazole Chemical Structure

Cas No.: 6506-37-2

Size 가격 재고 수량
1mg
US$114.00
Ship Within 10-14 Days

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Nimorazole (K-1900) is a nitroimidazole anti-infective.

Nimorazole significantly improves the effect of radiotherapeutic management of supraglottic and pharynx tumors and can be given without major side-effects [1, 2]. Nimorazole is the only such agent to have shown a significant effect in a randomized controlled trial in head and neck cancer [3].

References:
[1]. Overgaard, J., et al., A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol, 1998. 46(2): p. 135-46.
[2]. Roy, R.B., S.M. Laird, and L. Heasman, Treatment of trichomoniasis in the female. A comparison of metronidazole and nimorazole. Br J Vener Dis, 1975. 51(4): p. 281-4.
[3]. Henk, J.M., K. Bishop, and S.F. Shepherd, Treatment of head and neck cancer with CHART and nimorazole: phase II study. Radiother Oncol, 2003. 66(1): p. 65-70.

리뷰

Review for Nimorazole

Average Rating: 5 ★★★★★ (Based on Reviews and 3 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Nimorazole

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.